Science Explorer Back to mapMap
Discussion
Institution · HealthONE

Most cited papers from HealthONE

HealthONE

What are the most cited papers from HealthONE?

The most cited paper from HealthONE is "Sotorasib for Lung Cancers with KRAS p.G12C Mutation" (Ferdinandos Skoulidis et al., 2021), with 1,862 citations. Next come "KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors" (1,743) and "Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours" (974).

Showing 50 of 60 papers. Every paper with more than 41 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Sotorasib for Lung Cancers with KRAS p.G12C Mutation Ferdinandos Skoulidis et al. · New England Journal of Medicine Open access 4 Jun 2021 1,862
2 KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors David S. Hong et al. · New England Journal of Medicine Open access 20 Sep 2020 1,743
3 Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours David S. Hong et al. · British Journal of Cancer Open access Apr 2020 974
4 A Review of Progress in Clinical Photodynamic Therapy Zheng Wen Huang · Technology in Cancer Research & Treatment Open access Jun 2005 913
5 Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine Open access 26 Aug 2020 856
6 Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer John H. Strickler et al. · New England Journal of Medicine Open access 21 Dec 2022 515
7 Herbs as Medicines Lisa Corbin Winslow, David J. Kroll · Archives of Internal Medicine 9 Nov 1998 358
8 Summary of Results Using the Nucleus CI24M Implant to Record the Electrically Evoked Compound Action Potential Paul J. Abbas, Carolyn Brown, Jon K. Shallop et al. · Ear and Hearing Feb 1999 327
9 Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial Marwan G Fakih et al. · The Lancet Oncology 15 Dec 2021 303
10 First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors Gerald Steven Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau et al. · EClinicalMedicine Open access 30 Mar 2021 299
11 PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients Aung Naing et al. · Cancer Cell Open access Nov 2018 256
12 BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer Gerald Steven Falchook, Michael J. Millward, David S. Hong et al. · Thyroid Open access 6 Oct 2014 232
13 MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer Lars D. Engstrom et al. · Cancer Discovery Open access 8 Aug 2023 219
14 PREVENTION OF BREASTFEEDING TRAGEDIES Marianne R. Neifert · Pediatric Clinics of North America Apr 2001 215
15 Disease severity, scratching, and sleep quality in patients with atopic dermatitis Bruce G. Bender, Robert D. Ballard, Beth Canono et al. · Journal of the American Academy of Dermatology 15 Feb 2008 184
16 Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100 Grace Kho Dy et al. · Journal of Clinical Oncology Open access 25 Apr 2023 161
17 Mechanisms of Delayed Wound Healing by Commonly Used Antiseptics Gregory W. Thomas, Leonard T. Rael, Raphael Bar-Or et al. · The Journal of Trauma: Injury, Infection, and Critical Care 2009 158
18 Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 Mansoor Noorali Saleh, Manish R. Patel, Todd Michael Bauer et al. · Clinical Cancer Research Open access 22 Jul 2021 154
19 Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810 Gerald Steven Falchook, Rom S. Leidner, Elizabeth Stankevich et al. · Journal for ImmunoTherapy of Cancer Open access 22 Oct 2016 151
20 Direct-to-Consumer Pharmaceutical Advertising Andrew Robinson, Kirsten B. Hohmann, Julie I. Rifkin et al. · Archives of Internal Medicine 23 Feb 2004 144
21 The cesarean birth epidemic: Trends, causes, and solutions Richard P. Porreco, James A. Thorp · American Journal of Obstetrics and Gynecology Aug 1996 142
22 Detection and Localization of Intraepithelial Neoplasia and Invasive Carcinoma Using Fluorescence-Reflectance Bronchoscopy: An International, Multicenter Clinical Trial Eric S. Edell, Stephen C. Lam, Harvey Ira Pass et al. · Journal of Thoracic Oncology Open access 2009 125
23 Improvement of Tumor Response by Manipulation of Tumor Oxygenation During Photodynamic Therapy¶ Qun Chen, Zheng Wen Huang, Hua Chen et al. · Photochemistry and Photobiology 2002 124
24 Preclinical Studies in Normal Canine Prostate of a Novel Palladium-Bacteriopheophorbide (WST09) Photosensitizer for Photodynamic Therapy of Prostate Cancer¶ Qun Chen, Zheng Wen Huang, David L. Luck et al. · Photochemistry and Photobiology 2002 117
25 Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress Gerald Steven Falchook, Christel C. Bastida, Razelle Kurzrock · Seminars in Oncology 24 Sep 2015 115
26 Errors in drug administration by nurses Ginette A. Pepper · American Journal of Health-System Pharmacy Feb 1995 110
27 TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics Jennifer J. Wheler, Filip Jankú, Aung Naing et al. · Molecular Cancer Therapeutics 27 Jul 2016 107
28 Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response Ben S. Sidders, Pei Zhang, Kelly Goodwin et al. · Clinical Cancer Research 17 Jan 2020 106
29 A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer Elena Garralda, Ammar W. Sukari, Nehal J. Lakhani et al. · ESMO Open Open access Dec 2022 99
30 First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response Timothy Anthony Yap et al. · Clinical Cancer Research Open access 5 May 2022 98
31 Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer Gerald Steven Falchook et al. · JAMA Oncology Open access 22 Oct 2018 93
32 First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors Gerald Steven Falchook, Razelle Kurzrock, Hesham M. Amin et al. · Clinical Cancer Research Open access 10 Dec 2019 92
33 Low-Dose Chest CT: Optimizing Radiation Protection for Patients Xiaohua Zhu, Jianqun Yu, Zheng Huang · American Journal of Roentgenology Sep 2004 81
34 Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies Gerald Steven Falchook et al. · Clinical Cancer Research 16 Sep 2019 79
35 BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System Filip Jankú et al. · Molecular Cancer Therapeutics 22 May 2016 78
36 B7-H3 Inhibitors in Oncology Clinical Trials: A Review Kavanya Feustel, Jared D. Martin, Gerald Steven Falchook · Journal of Immunotherapy and Precision Oncology Open access 19 Dec 2023 77
37 PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer Danny Rischin et al. · Gynecologic Oncology Open access 9 Sep 2020 75
38 Studies of a vascular‐acting photosensitizer, Pd‐bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer Zheng Wen Huang, Qun Chen, David L. Luck et al. · Lasers in Surgery and Medicine Open access 26 Apr 2005 74
39 Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma David S. Hong, Razelle Kurzrock, Jennifer J. Wheler et al. · Clinical Cancer Research Open access 13 Jul 2015 71
40 Changes in In Vivo Optical Properties and Light Distributions in Normal Canine Prostate during Photodynamic Therapy Qun Chen, Brian C. Wilson, Sugandh D. Shetty et al. · Radiation Research 1997 69
41 BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity Maria E. Cabanillas, Ami P. Patel, Brian P. Danysh et al. · Hormones and Cancer Open access 2 Dec 2014 68
42 Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials Shiraj Sen, Roberto Carmagnani Pestana, Kenneth R. Hess et al. · Annals of Oncology Open access 10 Oct 2018 67
43 First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Albert Craig Lockhart et al. · Clinical Cancer Research 3 Dec 2019 65
44 Interstitial photodynamic therapy in the canine prostate L. K. Lee, Colin Whitehurst, Qixin Chen et al. · British Journal of Urology Dec 1997 65
45 Hyperoxygenation Enhances the Tumor Cell Killing of Photofrin-mediated Photodynamic Therapy¶ Zheng Wen Huang, Qun Chen, Abdus Shakil et al. · Photochemistry and Photobiology 2003 62
46 Clinical Aspects of Lactation Marianne R. Neifert · Clinics in Perinatology Jun 1999 60
47 A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors Gerald Steven Falchook, Marc Peeters, Sylvie Rottey et al. · Investigational New Drugs 14 Apr 2021 59
48 A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer Manish R. Patel, Gerald Steven Falchook, Kensuke Hamada et al. · Cancer Medicine Open access Feb 2021 57
49 Breastmilk Transfer: Positioning, Latch-on, and Screening for Problems in Milk Transfer Marianne R. Neifert · Clinical Obstetrics & Gynecology Sep 2004 55
50 Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy Haeseong Park, Ignacio Garrido‐Laguna, Aung Naing et al. · Oncotarget Open access 31 Aug 2016 52

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.